Aspire Biopharma logo
Aspire Biopharma
ASBP | NASDAQ
Chart Builder DCF Calculator
$8.06
-$0.35 (-4.16%)
At close: Nov 16, 2026, 4:00 PM ET
$8.30
+$0.24 (+2.98%)
After-hours: Nov 16, 2026, 7:30 PM ET

Aspire Biopharma Company Profile

Company profile explained

Company Profile

Aspire Biopharma Holdings, Inc. is an emerging pharmaceutical enterprise dedicated to pioneering and commercializing innovative sublingual drug delivery systems within the United States. Its flagship product, Instaprin, is an advanced sublingual aspirin formulation known for being soluble, pH neutral, and rapidly absorbed, making it effective for both cardiovascular emergencies and general pain management. The company is diligently developing a diverse pipeline of orally dissolving formulations. This includes a melatonin-based sleep aid, essential vitamins (D, E, and K), testosterone, and semaglutide. Furthermore, Aspire Biopharma is extending its sublingual development efforts to various therapeutic areas, such as anti-nausea treatments, antipsychotic medications, erectile dysfunction drugs, and seizure control therapies, among others. They are also exploring caffeine products, including a formulation for a single-dose sublingual pre-workout supplement. Established in 2021, the firm's main operational base is situated in Estero, Florida.

Key Executives

Name Position
Kraig T. Higginson Interim Chief Executive Officer, President & Executive Chairman of the Board
Ernest J. Scheidemann Jr. Chief Financial Officer
Stephen E. Quesenberry General Counsel & Corporate Secretary

Latest SEC Filings

Date Type Title
Oct 20, 2026 8-K/A [Amend] Current Report
Sep 29, 2026 8-K Current Report
Sep 09, 2026 8-K Current Report
Sep 08, 2026 8-K Current Report
Aug 19, 2026 8-K Current Report
Aug 14, 2026 SC 13G/A [Amend] Statement of acquisition of beneficial own...
Aug 13, 2026 10-Q Quarterly Report
Aug 10, 2026 SC 13G Statement of acquisition of beneficial ownership b...
Aug 10, 2026 8-K Current Report
Aug 06, 2026 SC 13G/A [Amend] Statement of acquisition of beneficial own...
View All SEC Filings ➞
Aspire Biopharma
Aspire Biopharma logo
Country United States
IPO Date Feb 20, 2025
Industry Medical - Pharmaceuticals
Sector Healthcare
Employees 2
CEO Kraig T. Higginson

Contact Details

23150 Fashion Drive Estero, Florida 33928 United States

Stock Details

Ticker Symbol ASBP
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001847345
CUSIP Number 738920305
ISIN Number US7389203057
SIC Code 6770

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.